Connection

Robert Harrington to Myocardial Ischemia

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Myocardial Ischemia.
Robert Harrington
Connection Strength
2.937
Myocardial Ischemia
  1. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. J Interv Cardiol. 2007 Oct; 20(5):299-306.
    View in: PubMed
    Score: 0.263
  2. Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities. Circulation. 2007 Jun 05; 115(22):2796-8.
    View in: PubMed
    Score: 0.258
  3. Myocardial ischemia and infarction. J Am Coll Cardiol. 2004 Jul 21; 44(2 Suppl A):10A-12A.
    View in: PubMed
    Score: 0.211
  4. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15; 116(2):119-29.
    View in: PubMed
    Score: 0.204
  5. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
    View in: PubMed
    Score: 0.145
  6. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
    View in: PubMed
    Score: 0.143
  7. Planning and Conducting the ISCHEMIA Trial. Circulation. 2018 10 02; 138(14):1384-1386.
    View in: PubMed
    Score: 0.141
  8. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 07; 201:124-135.
    View in: PubMed
    Score: 0.137
  9. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.130
  10. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016 Jan 05; 67(1):81-99.
    View in: PubMed
    Score: 0.116
  11. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.
    View in: PubMed
    Score: 0.114
  12. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
    View in: PubMed
    Score: 0.099
  13. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):246-55.
    View in: PubMed
    Score: 0.099
  14. Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013 07 25; 369(4):393-4.
    View in: PubMed
    Score: 0.099
  15. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 04; 368(14):1303-13.
    View in: PubMed
    Score: 0.096
  16. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.
    View in: PubMed
    Score: 0.085
  17. Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol. 2010 Dec 15; 106(12):1728-34.
    View in: PubMed
    Score: 0.081
  18. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis. 2006 Jun; 21(3):211-20.
    View in: PubMed
    Score: 0.060
  19. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. 2006 Jan 17; 47(2):312-8.
    View in: PubMed
    Score: 0.059
  20. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.
    View in: PubMed
    Score: 0.054
  21. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004 Oct 06; 292(13):1555-62.
    View in: PubMed
    Score: 0.054
  22. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15; 92(6):660-4.
    View in: PubMed
    Score: 0.050
  23. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.
    View in: PubMed
    Score: 0.039
  24. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.
    View in: PubMed
    Score: 0.033
  25. Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
    View in: PubMed
    Score: 0.031
  26. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
    View in: PubMed
    Score: 0.025
  27. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012 Feb; 163(2):182-90.e4.
    View in: PubMed
    Score: 0.022
  28. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.021
  29. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.
    View in: PubMed
    Score: 0.021
  30. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.
    View in: PubMed
    Score: 0.018
  31. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 07; 355(10):1006-17.
    View in: PubMed
    Score: 0.015
  32. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol. 2003 Aug 01; 92(3):330-3.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.